1
|
Dunn GP, Rinne ML, Wykosky J, Genovese G,
Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et
al: Emerging insights into the molecular and cellular basis of
glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classifcation of tumours of the central nervous system. Acta
Neuro Pathol. 114:97–109. 2007.
|
3
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer Clin. 67:7–30. 2017. View Article : Google Scholar
|
5
|
Liao AY, Shi RR, Jiang YL, Tian S, Li P,
Song F, Qu Y, Li J, Yun H and Yang X: SDF-1/CXCR4 axis regulates
cell cycle progression and epithelial-mesenchymal transition via
up-regulation of survivin in glioblastoma. Mol Neurobiol.
53:210–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Altieri R, Fontanella M, Agnoletti A,
Pnciani PP, Spena G, Crobeddu E, Pilloni G, Tardivo V, Lanotte M,
Zenga F, et al: Role of nitric oxide in glioblastoma therapy:
Another step to resolve the terrible puzzle. Transl Med UniSa.
12:54–59. 2014.PubMed/NCBI
|
7
|
De Paepe A, Vandeneede N, Strens D and
Specenier P: The economics of the treatment and follow-up of
patients with glioblastoma. Value Health. 18:A4482015. View Article : Google Scholar
|
8
|
Lv B, Yang X, Lv S, Wang L, Fan K, Shi R,
Wang F, Song H, Ma X, Tan X, et al: CXCR4 signaling induced
epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in
glioblastoma. Mol Neurobiol. 52:1263–1268. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lin SJ, Defossez PA and Guarente L:
Requirement of NAD and SIR2 for life-span extension by calorie
restriction in Saccharomyces cerevisiae. Science. 289:2126–2128.
2000. View Article : Google Scholar : PubMed/NCBI
|
10
|
Ford J, Jiang M and Milner J:
Cancer-specific functions of SIRT1 enable human epithelial cancer
cell growth and survival. Cancer Res. 65:10457–10463. 2005.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Smith JS, Brachmann CB, Celic I, Kenna MA,
Muhammad S, Starai VJ, Avalos JL, Escalante-Semerena JC, Grubmeyer
C, Wolberger C and Boeke JD: A phylogenetically conserved
NAD(+)-dependent protein deacetylase activity in the Sir2 protein
family. Proc Natl Acad Sci USA. 97:6658–6663. 2000. View Article : Google Scholar : PubMed/NCBI
|
12
|
Imai S, Armstrong CM, Kaeberlein M and
Guarente L: Transcriptional silencing and longevity protein Sir2 is
an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Saunders LR and Verdin E: Sirtuins:
Critical regulators at the crossroads between cancer and aging.
Oncogene. 26:5489–5504. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer-a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Choi HN, Bae JS, Jamiyandorj U, Noh SJ,
Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression
and role of SIRT1 in hepatocellular carcinoma. Oncol Rep.
26:503–510. 2011.PubMed/NCBI
|
17
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim
KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG and Moon WS:
Expression and prognostic significance of SIRT1 in ovarian
epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Jang KY, Hwang SH, Kwon KS, Kim KR, Choi
HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, et al: SIRT1
expression is associated with poor prognosis of diffuse large
B-cell lymphoma. Am J Surg Pathol. 32:1523–1531. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Qu Y, Zhang J, Wu S, Li B, Liu S and Cheng
J: SIRT1 promotes proliferation and inhibits apoptosis of human
malignant glioma cell lines. Neurosci Lett. 525:168–172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lopez-Valero I, Saiz-Ladera C, Torres S,
Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M,
Dávila D, Salvador-Tormo N, Guzmán M, et al: Targeting glioma
initiating cells with a combined therapy of cannabinoids and
temozolomide. Biochem Pharmacol. 157:266–274. 2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yamashita AS, da Costa Rosa M, Borodovsky
A, Festuccia WT, Chan T and Riggins GJ: Demethylation and
epigenetic modification with 5-Azacytidine reduces IDH1 mutant
glioma growth in combination with Temozolomide. Neuro Oncol.
2018.
|
25
|
Costa PM, Cardoso AL, Nóbrega C, Pereira
de Almeida LF, Bruce JN, Canoll P and Pedroso de Lima MC:
MicroRNA-21 silencing enhances the cytotoxic effect of the
antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet.
22:904–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Hung AL, Maxwell R, Theodros D, Belcaid Z,
Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, et al:
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity
and survival in GBM. Oncoimmunology. 7:e14667692018. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ruan Y, Dong CL, Patel J, Duan C, Wang X,
Wu X, Cao Y, Pu L, Lu D, Shen T and Li J: SIRT1 suppresses
doxorubicin-induced cardiotoxicity by regulating the oxidative
stress and p38MAPK pathways. Cell Physiol Biochem. 35:1116–1124.
2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen HC, Lu Q, Fei XF, Shen L, Jiang D and
Dai D: miR-22 inhibits the proliferation, motility, and invasion of
human glioblastoma cells by directly targeting SIRT1. Tumor Biol.
37:6761–6768. 2016. View Article : Google Scholar
|
29
|
Zhou YF, Zhou Z, Zhang W, Hu X, Wei H,
Peng J and Jiang S: SIRT1 inhibits adipogenesis and promotes
myogenic differentiation in C3H10T1/2 pluripotent cells by
regulating Wnt signaling. Cell Biosci. 5:612015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Shuang T, Wang M, Zhou Y and Shi C:
Over-expression of Sirt1 contributes to chemoresistance and
indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Med Oncol. 32:2602015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Linz U: Commentary on Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet
Oncol. 2009;10:459-466). Cancer. 116:1844–1846. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Gaspar N, Marshall L, Perryman L, Bax DA,
Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis
RM, et al: MGMT-independent temozolomide resistance in pediatric
glioblastoma cells associated with a PI3-kinase-mediated HOX/stem
cell gene signature. Cancer Res. 70:9243–9252. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Pyko IV, Nakada M, Sabit H, Teng L,
Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS and
Hamada J: Glycogen synthase kinase 3β inhibition sensitizes human
glioblastoma cells to temozolomide by affecting O6-methylguanine
DNA methyltransferase promoter methylation via c-Myc signaling.
Carcinogenesis. 34:2206–2217. 2013. View Article : Google Scholar : PubMed/NCBI
|